留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

硫利达嗪抗宫颈癌的潜在作用机制

谢芹,  赵春阳,  张葆溯,  赵洪波

downloadPDF
文章导航 > 昆明医科大学学报  > 2022 >  43(3): 13-20
谢芹, 赵春阳, 张葆溯, 赵洪波. 硫利达嗪抗宫颈癌的潜在作用机制[J]. 昆明医科大学学报, 2022, 43(3): 13-20. doi: 10.12259/j.issn.2095-610X.S20220317
引用本文: 谢芹, 赵春阳, 张葆溯, 赵洪波. 硫利达嗪抗宫颈癌的潜在作用机制[J]. 昆明医科大学学报, 2022, 43(3): 13-20. doi: 10.12259/j.issn.2095-610X.S20220317
shu
Qin XIE, Chunyang ZHAO, Baosu ZHANG, Hongbo ZHAO. Potential Mechanism of Thioridazine in Anti-cervical Cancer[J]. Journal of Kunming Medical University, 2022, 43(3): 13-20. doi: 10.12259/j.issn.2095-610X.S20220317
Citation: Qin XIE, Chunyang ZHAO, Baosu ZHANG, Hongbo ZHAO. Potential Mechanism of Thioridazine in Anti-cervical Cancer[J]. Journal of Kunming Medical University, 2022, 43(3): 13-20. doi: 10.12259/j.issn.2095-610X.S20220317
shu

硫利达嗪抗宫颈癌的潜在作用机制

doi: 10.12259/j.issn.2095-610X.S20220317

  • 昆明医科大学生物医学工程研究院暨云南省干细胞和再生医学重点实验室，云南 昆明　650500

基金项目: 云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目（202101AY070001-075）；云南省教育厅科学研究基金资助项目（2021J0226）
详细信息
    作者简介:

    谢芹（1997～），女，四川安岳人，在读硕士研究生，主要从事生物信息，网络药理学研究工作

    通讯作者:

    赵洪波，E-mail：zhaohongbo@kmmu.edu.cn

  • 中图分类号: R737.3

Potential Mechanism of Thioridazine in Anti-cervical Cancer

  • Institute of Biomedical Engineering & Yunnan Key Laboratory of Stem Cell and Regenerative Medicine，Kunming Medical University，Kunming Yunnan 650500，China

    摘要
  • 摘要:   目的  运用生物信息学分析， 探讨硫利达嗪抗宫颈癌的潜在作用机制。  方法  通过PharmMapper工具预测能够与硫利达嗪相互作用的靶基因，然后使用STRING在线工具对靶基因进行通路和组织表达富集分析。使用GeneCards和DisGeNET数据库筛选宫颈癌相关基因，与硫利达嗪的靶基因取交集，得到硫利达嗪可能作用于宫颈癌的交互基因。通过STRING构建蛋白互作（PPI）网络，推测核心靶点，评估其重要性。使用clusterProfiler软件进行GO和KEGG通路分析。  结果  通过PharmMapper预测得到47个靶基因，富集到肿瘤相关通路和宫颈癌细胞。与669个宫颈癌基因取交集，获得硫利达嗪和宫颈癌交互基因21个，其中10个关键节点基因为EGFR、PPARG、AR、NOS3、ALB、ESR1、MAPK1、MAPK14、ANXA5和MAPK8，且在宫颈癌PPI网络中处于重要位置。交互基因涉及到的生物进程主要有负离子转运的正调控、丝氨酸肽基磷酸化、类固醇代谢过程、血液凝固、细胞对化学应激的反应等。富集的KEGG通路包括调控癌症通路、松弛素信号通路、内分泌耐药、蛋白聚糖与肿瘤、细胞衰老、GnRH信号通路和VEGF信号通路等。  结论  硫利达嗪具有潜在的抗肿瘤作用，可能通过多靶点和多信号通路的方式在宫颈癌的治疗上发挥作用。
    Abstract:   Objective  To explore the potential mechanism of thioridazine in the treatment of cervical cancer by bioinformatics analysis.   Methods  The target genes that can interact with thioridazine was predicted by PharmMapper, and then conducted pathway and tissue expression enrichment analysis by STRING online tool. The cervical cancer related genes were screened through GeneCards and DisGeNET databases, and cross the target genes of thioridazine to obtain the interaction genes that thioridazine may act on cervical cancer. The protein-protein interaction（PPI） network was constructed using STRING, and the core targets were speculated and evaluated their importance．The GO and KEGG enrichment analysis were conducted using clusterProfiler package.   Results  A total of 47 target genes were predicted by PharmMapper, which were enriched in tumor-related pathways and cervical cancer cells. Intersection with 669 cervical cancer genes, 21 common genes were obtained, of which 10 key genes were EGFR, PPARG, AR, NOS3, ALB, ESR1, MAPK1, MAPK14, ANXA5 and MAPK8. These key genes were important in the cervical cancer PPI network. The biological processes involved in interactive genes mainly include positive regulation of anion transport, peptidyl-serine phosphorylation, steroid metabolic process, blood coagulation, and cellular response to chemical stress. Enriched KEGG pathways include pathways in cancer, relaxin signaling pathway, endocrine resistance, proteoglycans in cancer, cellular senescence, GnRH signaling pathway, and VEGF signaling pathway.   Conclusion  Thioridazine has potential anti-tumor effects and may play a role in the treatment of cervical cancer through multiple targets and multiple signaling pathways.
    • HTML全文

  • 图  1  宫颈癌基因和硫利达嗪靶基因的Upset图

    Figure  1.  Upset map of cervical cancer genes and thioridazine target genes

    下载: 全尺寸图片 幻灯片

    图  2  交互基因的蛋白互作网络图

    Figure  2.  PPI network of interacting genes

    下载: 全尺寸图片 幻灯片

    图  3  关键靶基因的蛋白互作网络图

    Figure  3.  PPI network of key target genes

    下载: 全尺寸图片 幻灯片

    图  4  GO富集分析结果

    Figure  4.  Results of GO enrichment analysis

    下载: 全尺寸图片 幻灯片

    图  5  KEGG通路富集分析结果

    Figure  5.  Results of KEGG pathway enrichment analysis

    下载: 全尺寸图片 幻灯片

    表  1  排名前10的靶基因通路分析结果

    Table  1.   Top10 pathways results of target genes

    ID号名称基因数FDR
    hsa04926松弛素信号通路91.50E-08
    hsa05200肿瘤通路134.88E-08
    hsa01522内分泌耐药76.70E-07
    hsa05205蛋白聚糖与肿瘤83.01E-06
    hsa05166人类T细胞白血病
    病毒1感染    		84.18E-06
    hsa04218细胞衰老76.70E-06
    hsa04912促性腺激素释放
    激素信号通路    		66.70E-06
    hsa04914孕酮介导的卵
    母细胞成熟    		67.36E-06
    hsa05161乙型肝炎77.36E-06
    hsa04933糖尿病并发症中
    的AGE-RAGE信号通路    		67.85E-06
    下载: 导出CSV

    表  2  排名前10的靶基因疾病富集分析结果

    Table  2.   Top10 disease enrichment results of target genes

    ID号名称基因数FDR
    DOID：162肿瘤120.0022
    DOID：14566细胞增殖疾病130.0022
    DOID：4疾病310.0022
    DOID：65结缔组织疾病100.0064
    DOID：7解剖实体疾病250.0064
    DOID：0050636家族性内脏
    淀粉样变性    		30.0183
    DOID：28内分泌系统疾病70.0183
    DOID：0080001骨疾病80.0184
    DOID：11801蛋白质-能量营
    养不良    		20.0184
    DOID：0060075雌激素受体
    阳性乳腺癌    		20.0244
    下载: 导出CSV

    表  3  排名前10的靶基因组织表达富集分析

    Table  3.   Top10 tissue expression enrichment results of target genes

    ID号名称基因数FDR
    BTO：0000180宫颈癌细胞102.03E-06
    BTO：0000174胚胎结构222.03E-06
    BTO：0000759肝202.71E-06
    BTO：0000132血小板104.54E-06
    BTO：0001078胎盘164.54E-06
    BTO：0001546慢性淋巴细胞
    白血病细胞    		88.77E-06
    BTO：0001489全身469.93E-06
    BTO：0000345消化腺221.02E-05
    BTO：0001491脏器301.07E-05
    BTO：0000522腺体341.77E-05
    下载: 导出CSV

    表  4  关键靶基因在宫颈癌PPI网络中的排名

    Table  4.   Ranking of key target genes in the cervical cancer PPI network

    靶基因Degree值排名
    EGFR3296
    ALB27113
    ESR125520
    ANXA520032
    PPARG18237
    AR15953
    MAPK114372
    MAPK1414177
    MAPK813879
    NOS3105127
    合计525
    下载: 导出CSV
    • 参考文献(37)
  • [1] Sung H,Ferlay J,Siegel R L,et al. Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249. doi: 10.3322/caac.21660
    [2] de Foucher T,Bendifallah S,Ouldamer L,et al. Patterns of recurrence and prognosis in locally advanced FIGO stage IB2 to IIB cervical cancer:Retrospective multicentre study from the FRANCOGYN group[J]. Eur J Surg Oncol,2019,45(4):659-665. doi: 10.1016/j.ejso.2018.11.014
    [3] Fenton M,Rathbone J,Reilly J,et al. Thioridazine for schizophrenia[J]. Cochrane Database Syst Rev,2007,2007(3):CD001944.
    [4] Duarte D,Cardoso A,Vale N. Synergistic growth inhibition of HT-29 colon and MCF-7 breast cancer cells with simultaneous and sequential combinations of antineoplastics and CNS drugs[J]. Int J Mol Sci,2021,22(14):7408. doi: 10.3390/ijms22147408
    [5] Tegowski M,Fan C,Baldwin A S. Selective effects of thioridazine on self-renewal of basal-like breast cancer cells[J]. Sci Rep,2019,9(1):18695. doi: 10.1038/s41598-019-55145-3
    [6] Mu J,Xu H,Yang Y,et al. Thioridazine,an antipsychotic drug,elicits potent antitumor effects in gastric cancer[J]. Oncol Rep,2014,31(5):2107-2114. doi: 10.3892/or.2014.3068
    [7] Lu M,Li J,Luo Z,et al. Roles of dopamine receptors and their antagonist thioridazine in hepatoma metastasis[J]. Onco Targets Ther,2015,8(default):1543-1552.
    [8] Cheng H W,Liang Y H,Kuo Y L,et al. Identification of thioridazine,an antipsychotic drug,as an antiglioblastoma and anticancer stem cell agent using public gene expression data[J]. Cell Death Dis,2015,6(5):e1753. doi: 10.1038/cddis.2015.77
    [9] Hercbergs A. Thioridazine:a radiation enhancer in advanced cervical cancer?[J]. Lancet,1988,2(8613):737.
    [10] Mao M,Yu T,Hu J,et al. Dopamine D2 receptor blocker thioridazine induces cell death in human uterine cervical carcinoma cell line SiHa[J]. J Obstet Gynaecol Res,2015,41(8):1240-1245. doi: 10.1111/jog.12691
    [11] Wang X,Shen Y,Wang S,et al. PharmMapper 2017 update:a web server for potential drug target identification with a comprehensive target pharmacophore database[J]. Nucleic Acids Res,2017,45(W1):W356-W360. doi: 10.1093/nar/gkx374
    [12] Szklarczyk D,Gable A L,Lyon D,et al. STRING v11:protein-protein association networks with increased coverage,supporting functional discovery in genome-wide experimental datasets[J]. Nucleic Acids Res,2019,47(D1):D607-D613. doi: 10.1093/nar/gky1131
    [13] Stelzer G,Rosen N,Plaschkes I,et al. The gene cards suite:From gene data mining to disease genome sequence analyses[J]. Curr Protoc Bioinformatics,2016,54:1.30.1-1.30.33.
    [14] Piñero J,Ramírez-Anguita J M,Saüch-Pitarch J,et al. The DisGeNET knowledge platform for disease genomics:2019 update[J]. Nucleic Acids Res,2020,48(D1):D845-D855.
    [15] Chin C H,Chen S H,Wu H H,et al. cytoHubba:identifying hub objects and sub-networks from complex interactome[J]. BMC Syst Biol,2014,8(Suppl 4):S11.
    [16] Wu T,Hu E,Xu S,et al. clusterProfiler 4.0:A universal enrichment tool for interpreting omics data[J]. Innovation (N Y),2021,2(3):100141.
    [17] Hartman Z,Geldenhuys W J,Agazie Y M. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2)[J]. J Biol Chem,2020,295(11):3563-3575. doi: 10.1074/jbc.RA119.011422
    [18] Peng Z,Wang Q,Zhang Y,et al. EBP50 interacts with EGFR and regulates EGFR signaling to affect the prognosis of cervical cancer patients[J]. Int J Oncol,2016,49(4):1737-1745. doi: 10.3892/ijo.2016.3655
    [19] Ding L and Zhang H. Circ-ATP8A2 promotes cell proliferation and invasion as a ceRNA to target EGFR by sponging miR-433 in cervical cancer[J]. Gene,2019,705:103-108. doi: 10.1016/j.gene.2019.04.068
    [20] Mustafa H A,Albkrye A M S,AbdAlla B M,et al. Computational determination of human PPARG gene:SNPs and prediction of their effect on protein functions of diabetic patients[J]. Clin Transl Med,2020,9(1):7.
    [21] Wuertz B R,Darrah L,Wudel J,et al. Thiazolidinediones abrogate cervical cancer growth[J]. Exp Cell Res,2017,353(2):63-71. doi: 10.1016/j.yexcr.2017.02.020
    [22] Noël J C,Bucella D,Fayt I,et al. Androgen receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix[J]. Int J Gynecol Pathol,2008,27(3):437-441. doi: 10.1097/PGP.0b013e318160c599
    [23] Vannini F,Kashfi K,Nath N. The dual role of iNOS in cancer[J]. Redox Biol,2015,6:334-343. doi: 10.1016/j.redox.2015.08.009
    [24] Topchieva L V,Balan O V,Korneva V A,et al. The nitric oxide metabolite level and NOS2 and NOS3 gene transcripts in patients with essential arterial hypertension[J]. Biology Bulletin,2020,47(3):247-252. doi: 10.1134/S1062359020010161
    [25] Gray S,Axelsson B. The prevalence of deranged C-reactive protein and albumin in patients with incurable cancer approaching death[J]. PLoS One,2018,13(3):e0193693. doi: 10.1371/journal.pone.0193693
    [26] Hoogenboezem E N,Duvall C L. Harnessing albumin as a carrier for cancer therapies[J]. Adv Drug Deliv Rev,2018,130:73-89. doi: 10.1016/j.addr.2018.07.011
    [27] Chung S H,Wiedmeyer K,Shai A,et al. Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer[J]. Cancer Res,2008,68(23):9928-9934. doi: 10.1158/0008-5472.CAN-08-2051
    [28] Yu P,Wang Y,Li C,et al. Protective effects of downregulating estrogen receptor alpha expression in cervical cancer[J]. Anticancer Agents Med Chem,2018,18(14):1975-1982.
    [29] Chen Y,Gu Y,Gu Y,et al. Long noncoding RNA LINC00899/miR-944/ESR1 axis regulates cervical cancer cell proliferation,migration,and invasion[J]. J Interferon Cytokine Res,2021,41(6):220-233. doi: 10.1089/jir.2021.0023
    [30] Xiao M,Feng Y,Cao G,et al. A novel MtHSP70-FPR1 fusion protein enhances cytotoxic T lymphocyte responses to cervical cancer cells by activating human monocyte-derived dendritic cells via the p38 MAPK signaling pathway[J]. Biochem Biophys Res Commun,2018,503(3):2108-2116. doi: 10.1016/j.bbrc.2018.07.167
    [31] Li X,Chen L,Liang X J,et al. Annexin A5 protein expression is associated with the histological differentiation of uterine cervical squamous cell carcinoma in patients with an increased serum concentration[J]. Mol Med Rep,2012,6(6):1249-1254. doi: 10.3892/mmr.2012.1078
    [32] Li X,Ma W,Wang X,et al. Annexin A5 overexpression might suppress proliferation and metastasis of human uterine cervical carcinoma cells[J]. Cancer Biomark,2018,23(1):23-32. doi: 10.3233/CBM-171040
    [33] Youn M J,So H S,Cho H J,et al. Berberine,a natural product,combined with cisplatin enhanced apoptosis through a mitochondria/caspase-mediated pathway in HeLa cells[J]. Biol Pharm Bull,2008,31(5):789-795. doi: 10.1248/bpb.31.789
    [34] Ng H H,Shen M,Samuel C S,et al. Relaxin and extracellular matrix remodeling:Mechanisms and signaling pathways[J]. Mol Cell Endocrinol,2019,487:59-65. doi: 10.1016/j.mce.2019.01.015
    [35] Claesson-Welsh L,Welsh M. VEGFA and tumour angiogenesis[J]. J Intern Med,2013,273(2):114-127. doi: 10.1111/joim.12019
    [36] Chuai Y,Rizzuto I,Zhang X,et al. Vascular endothelial growth factor (VEGF) targeting therapy for persistent,recurrent,or metastatic cervical cancer[J]. Cochrane Database Syst Rev,2021,2021(3):CD013348.
    [37] Li J,Yao Q Y,Xue J S,et al. Dopamine D2 receptor antagonist sulpiride enhances dexamethasone responses in the treatment of drug-resistant and metastatic breast cancer[J]. Acta Pharmacol Sin,2017,38(9):1282-1296. doi: 10.1038/aps.2017.24
    • 相关文章(20)
  • [1] 孟丽燕, 王超群, 陈星慧, 何军晶, 牛雅茹, 马丽莎.  早期宫颈癌术后HPV持续感染的危险因素分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240422
    [2] 杨梅, 王平, 杨晖, 何功浩.  心力衰竭的潜在治疗靶点及相关药物研发进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230719
    [3] 刘倩, 哈提拉·吐尔逊, 阿仙姑·哈斯木.  HLA-G通过促进活化性受体的表达增强NK细胞对宫颈癌细胞的杀伤作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220714
    [4] 许悦, 王婵, 林纾丞, 张慧洁, 澹忆, 张树威, 曾晓锋, 李桢.  α-鹅膏毒肽诱导肝细胞毒性作用机制的研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20221228
    [5] 刘洋, 廖婧, 卢又汇, 孙春意, 孟昱时.  miR-21负向调控宫颈癌HeLa细胞株中hTERT的表达, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210307
    [6] 谭丁及, 尹洪莉, 朱锐, 张曦, 余鑫, 飞勇, 李昕, 段铭, 何亮, 杨宏英.  宫颈上皮内瘤变和宫颈癌患者的阴道微生态特点, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210821
    [7] 张娟, 张红芸.  宫颈管搔刮术在宫颈癌筛查中的价值, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210822
    [8] 郝立君, 徐丽秀, 李金秋, 马俊旗, 阿仙姑·哈斯木.  肽基脯氨酰同分异构酶（Pin1）对子宫颈癌细胞脂质代谢的作用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210111
    [9] 卿清, 刘洋, 周红林.  宫颈癌筛查策略的研究进展, 昆明医科大学学报.
    [10] 翟淑娟, 潘景, 孙春意, 刘洋, 杨莹莹, 周红林.  p62、OPTN在宫颈癌中的表达及其与HPV的相关性, 昆明医科大学学报.
    [11] 周栩茹, 王熙, 田洁, 谢玲玲, 许宏宇, 李晓兰.  黏附斑激酶在宫颈癌组织中表达及意义, 昆明医科大学学报.
    [12] 李正金.  13种高危型HPV感染联合TCT检查在大理地区宫颈癌筛查中的应用, 昆明医科大学学报.
    [13] 朱胜章.  宫颈液基细胞学检查在贵州黔南地区宫颈癌筛查中的临床运用, 昆明医科大学学报.
    [14] 张祖娴.  昆明市高校女教师宫颈癌认知度与筛查现状分析, 昆明医科大学学报.
    [15] 廉阳秧.  中晚期宫颈癌组织HIF-1α、Twist、MDR1的表达及意义, 昆明医科大学学报.
    [16] 何红芬.  宫颈锥切术治疗IaⅠ期宫颈癌患者术后病灶残余状况及其危险因素, 昆明医科大学学报.
    [17] 肖肖.  YB-1在中晚期宫颈癌组织中的表达及其临床意义, 昆明医科大学学报.
    [18] 魏洁.  Twist在中晚期宫颈癌组织中的表达及临床意义研究, 昆明医科大学学报.
    [19] 刘慧瑾.  宫颈癌组织Vimentin的表达与淋巴转移宫旁浸润的关系研究, 昆明医科大学学报.
    [20] 黄雅.  Brn-3a、PPAR-γ在宫颈癌及癌前病变中的表达, 昆明医科大学学报.
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
图(5) / 表(4)
计量
  • 文章访问数:  3247
  • HTML全文浏览量:  2418
  • PDF下载量:  30
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-02-01
  • 网络出版日期:  2022-02-18
  • 刊出日期:  2022-03-22

目录

    /

    返回文章
    返回

    版权所有 © 《昆明医科大学学报》编辑部  滇ICP备00000000号-0

    编辑出版：昆明医科大学学报编辑部

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计